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ABSTRACT
A 14mer peptide (T14) derived from the C-terminus of acetylcholinesterase 
(AChE) selectively activates metastatic breast cancer cells via the alpha-7 nicotinic 
receptor (α7 nAChR). This naturally occurring peptide is also present in brain, is 
elevated in Alzheimer’s disease, and is antagonised by a cyclized variant (NBP-14). 
Here we investigated the effects of NBP-14 in six different cancer cell lines, primary 
leukemia B-cells and normal B-cells. All cells tested expressed α7 nAChR, intracellular 
and extracellular T14. However, NBP-14 showed low toxicity and weak anti-
proliferative effects in the majority of the cell lines and was even less toxic in normal 
B-cells when compared to primary chronic lymphocytic leukemia cells (P < 0.001). 
Given the potential role of T14 peptide in metastasis, we next investigated the effects 
of NBP-14 on tumor cell migration, where it caused a dose-dependent reduction. 
The extent of NBP-14 inhibition positively correlated with the migration of the cells 
(r2 = 0.45; P = 0.06). Furthermore, NBP-14 preferentially inhibited the migration 
of primary leukemia cells when compared with normal B-cells (P = 0.0002); when 
the normal B-cell data was excluded, this correlation was strengthened (r2 = 0.80; 
P = 0.006). Importantly, the constitutive α7 nAChR expression positively correlated 
with intracellular T14 levels (r2 = 0.91; P = 0.0003) and inversely correlated with 
extracellular T14 levels in the cell culture supernatants (r2 = −0.79; P = 0.034). 
However, in the presence of NBP-14, α7 nAChR expression was reduced (P = 0.04) and 
the most migratory cells showed the largest reduction in expression. In conclusion, 
NBP-14-mediated antagonism of the α7 nAChR offers a novel therapeutic strategy 
with the potential to inhibit tumor cell migration.
INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) are 
ligand-gated ion channels expressed in the cell membrane 
of a wide range of mammalian cells, including cancer 
cells [1]. Recent findings suggest that nAChRs not only 
mediate diverse functions in the brain, such as learning, 
memory, addiction and general plasticity [2] but may 
also contribute to the development and progression of 
a diverse array of cancers [3]. Binding of acetylcholine 
to the α subunits of nAChRs results in a conformational 
change in the receptor allowing ions to flow from the 
extracellular space into the cell [4]. The influx of the 
cations causes membrane depolarization which in 
turn triggers the opening of voltage-activated calcium 
channels, leading to an additional influx of calcium. 
This promotes a host of diverse responses, including the 
release of neurotransmitters and angiogenic, neurotrophic 
and growth factors. In addition, the increased intracellular 
cation concentrations may trigger the direct stimulation 
of intracellular signaling cascades that are involved in the 
regulation of cell proliferation, apoptosis, migration and 
differentiation [5].
Over the last 45 years [6] a link between cancer 
cell proliferation and acetycholinesterase (AChE) has 
become increasingly well established. In addition to its 
conventional enzymatic role in hydrolyzing acetylcholine, 
AChE could have an effect in cancer, independent of 
cholinergic transmission, that involves a variety of 
potential functions such as cell adhesion, differentiation, 
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regulation of apoptosis and proliferation [7]. One potential 
clue for these novel actions of AChE is the shift in patterns 
of oligomerization characterised during metastases, 
where the typical tetramer of four catalytic subunits 
disappears in favour of an increased number of dimers and 
monomers [8]. A possible explanation for this shift could 
be that the disulphide bond necessary for oligomerization 
is no longer intact, due to the cleavage of a constituent 
14mer peptide (T14) at the C-terminal of AChE [9], 
rendering it available to act as a signaling molecule. 
In a previous study, we showed that T14 had a 
selective action on the strongly metastatic breast cancer 
cell line MDA-MB-231 via the α7 nAChR. In contrast, 
these effects were not evident on the less metastatic cell 
line MCF-7 [10]. Accordingly, the initial aim of this study 
was to investigate whether endogenous α7 nAChR and 
T14 could be detected in a range of cancer cell lines and 
primary malignant and non-malignant cells. Furthermore, 
since recent observations have indicated that the action 
of the AChE-peptide T14 on brain tissue can be blocked 
by a cyclized variant (NBP-14) [11], we characterized the 
effects of this cyclized variant in a range of human cancer 
cell lines as well as primary chronic lymphocytic leukemia 
cells and normal B-cells. 
Here we show for the first time that the α7 nAChR 
plays a key role in modulating tumor cell migration. 
Moreover, there was a positive correlation between 
intracellular T14 and α7 nAChR expression and an inverse 
correlation between extracellular T14 derived from the 
culture media and α7 nAChR expression. We further 
demonstrate that exposure to the α7 nAChR antagonist 
and cyclized variant of T14, NBP-14, results in reduced 
tumor cell migration without any significant loss in cell 
viability. Furthermore, NBP-14 appears to preferentially 
effect tumor cell migration as normal B-cells were less 
sensitive to this cyclic peptide. The combination of these 
characteristics suggests that targeting the α7 nAChR may 
be a promising therapeutic strategy particularly in cancers 
with a strong metastatic potential. 
RESULTS
Intracellular and extracellular T14 expression 
correlate with α7 nAChR expression
Our first goal was to determine whether we could 
detect the T14 peptide in samples collected from each of 
the cell lines and primary cells. We performed Western 
blot analysis for T14 and α7 nAChR on cell lysates and 
aliquots of the cell culture media. The α7 nAChR was not 
detectable in the cell culture media (data not shown) but 
was consistently detected in the cell lysates (Figure 1A). 
α7 nAChR expression levels were normalized to a 
GAPDH loading control revealing differential expression 
of α7 nAChR in the various cell lines. In contrast, T14 was 
detectable in both the cell lysates (Figure 1B) and the cell 
culture media (Figure 1C). It is worthy of note that T14 
was also detected in cell-free media containing 10% fetal 
calf serum but this could not explain the quantitatively 
different T14 levels found in the cell lysates and cell culture 
supernatants. As previously described, T14 was detected as 
aggregates rather than as a monomeric form [12] thereby 
explaining the higher than expected molecular weight of the 
Western blot band. Furthermore, there was a strong positive 
correlation between intracellular T14 and α7 nAChR 
expression (Figure 1D; r2 = 0.91) and an inverse correlation 
between extracellular T14 derived from the culture media 
and α7 nAChR expression (Figure 1E; r2 = −0.79). 
NBP-14 demonstrates low cytotoxic and only 
modest anti-proliferative effects
All of the primary cells and cell lines used in 
this study were shown to express varying levels of the 
α7 nAChR (Figure 2A). Treatment with the α7 nAChR 
antagonist NBP-14 showed modest apoptotic effects 
in all of the cell lines tested at concentrations > 0.1 µM 
(Figure 2B). Comparison of the apoptotic effects of 
NBP-14, T15 and T30 in each of the cell lines are 
shown in Supplementary Figure 1. Although MCF7 cells 
showed significantly increased sensitivity to NBP-14, 
these cells were equally sensitive to the effects of a 
control peptide (T15) consisting of the inert C-terminal 
15 amino acid residues of the neuro-active peptide (T30) 
suggesting that these effects were non-specific (Figure 2C). 
Furthermore, NBP-14 was essentially non-toxic in normal 
B-cells at the concentrations tested and was significantly 
more toxic in malignant B-cells derived from chronic 
lymphocytic leukemia (CLL) patients (Figure 2D; 
P < 0.001). In terms of anti-proliferative activity, 
NBP-14 only showed evidence of cytostatic effects at 
concentrations of > 0.1 µM (Figure 2E). Comparison of 
the anti-proliferative effects of NBP-14, T15 and T30 in 
each of the cell lines are shown in Supplementary Figure 2.
NBP-14 preferentially inhibits the migration of 
primary cancer cells 
We next established the migratory potential of all 
of the primary cells and cell lines employed in this study 
using transwell assays. There was inherent variation in the 
propensity of these cells to migrate along a chemokine 
or serum gradient over a 24 h time period (Figure 3A). 
Interestingly, there was a positive correlation between 
α7 nAChR expression, as measured by flow cytometry, 
and baseline migration of the cell lines and primary cells 
investigated in this study although this did not reach 
statistical significance (Figure 3B; r2 = 0.31). Noting 
these differences, we examined the effect on migration of 
the α7 nAChR inhibitory peptide NBP-14 over a range of 
concentrations. Figure 3C shows dose-response curves for 
effect of NBP-14 on the migration of the six cancer cell 
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lines. Given that the cell lines (apart from MCF7 cells) 
showed a significant reduction in migration following 
exposure to 1 µM NBP-14, we went on to determine 
the relative effects of 1µM of the inert T15 peptide, the 
T30 peptide containing the 14 amino acid sequence of 
T14 and the cyclized NBP-14 peptide in primary CLL 
cells, normal B-cells (n = 5) and each of the cell lines. 
Samples derived from ten CLL patients showed inherent 
differences in migration (Figure 3D) but all showed a 
significant reduction in migration when cultured in the 
presence of 1 µM NBP-14. In contrast, culture with T15 
and T30 had no significant effect. The co-administration 
of T30 and NBP-14 had no significant effect beyond that 
achieved with NBP-14 alone. Normal B-cells also showed 
a significant reduction migration following exposure to 
NBP-14 (Figure 3E). However, despite manifesting similar 
Figure 1: (A) α7 nAChR expression was assessed in whole cell lysates (1 × 106 cells) from each cell type using Western blotting. Protein 
bands were quantified using Image J and the α7 nAChR expression was normalized to GAPDH in order to determine the relative expression 
of α7 nAChR in the cell lines and primary cells under investigation. (B) T14 levels in cell lysates were quantified in the same way and 
(C) the level of T14 present in complete media was subtracted from cell culture media derived from each of cell lines and primary cells, 
before normalising to total protein using Blot FastStain. (D) α7 nAChR positively correlated with intracellular T14 expression (r2 = 0.91, 
P = 0.0003) and (E) negatively correlated with the levels of T14 detected in the culture media (r2 = −0.79, P = 0.0034). Graphs display the 
lines of best fit together with the 95% confidence intervals.
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Figure 2: (A) Comparison of α7 nAChR expression on the surface of the cancer cell lines and primary cells used in the study. In each 
case cells not labelled with antibody were analyzed to determine the level of autofluorescence (open histograms). (B) Cytotoxic dose-
response curves were generated from flow cytometric analysis using Annexin V and propidum iodide labeling of each of the cancer cell 
lines following exposure to increasing concentrations of NBP-14 for 72 h. (C) Comparison of the apoptotic effects of the cyclized peptide 
(NBP-14), the inert peptide T15, the T30 peptide containing the T14 active peptide amino acid sequence and the combination of NBP-14 
and T30 in MCF-7 breast cancer cells. (D) The cytotoxic effect of NBP-14 on primary CLL cells (n = 5) and normal B-cells (n = 3). (E) 
NBP-14 induced a dose-dependent decrease in proliferation in all of the cell lines tested. All data are presented as mean (± SD). *P < 0.05 
and **P < 0.001.
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levels of basal migration to leukemic CLL cells (P = 0.4), 
normal B-cells were significantly less sensitive to the 
effects of NBP-14 when compared with malignant B-cells 
derived from CLL patients (Figure 3F; P = 0.0002). It is 
possible that this may be attributable to the lower levels of 
α7 nAChR expressed on normal B-cells when compared 
to primary CLL cells. 
NBP-14 inhibits the migration of diverse cancer 
cell lines
Having established that NBP-14 had preferential 
anti-migratory effects on primary cancer cells, we went 
on to investigate the effects of NBP-14 on breast cancer, 
multiple myeloma, acute myeloid leukemia and CLL cell 
lines (Figure 4A–4F). With the exception of MCF-7 cells, 
all of the other cell lines showed a significant reduction 
in migration when treated with 1 µM NBP-14. As was 
the case with primary CLL cells, the co-administration 
of T30 and NBP-14 had no additional effect on migration 
when compared with NBP-14 alone. It is worthy of note 
that KG1a cells do not express CXCR4, the receptor for 
the chemokine CXCL12, and so in this case migration 
was promoted by the addition of 20% FCS into the 
basolateral chamber of the transwells. NBP-14 was 
able to inhibit the migration of KG1a cells under these 
conditions suggesting that the mechanism of inhibition is 
independent of chemokine receptor expression.
Basal migration predicts for response to NBP-14
Having established that the different cell lines and 
primary cells had inherent differences in basal migration, 
we examined whether this was predictive of response to 
NBP-14. Figure 5A shows the cell lines ranked according 
to the percentage decrease in migration induced by 1 µM 
NBP-14. There was a clear correlation between basal 
migration and the percentage decrease in migration 
induced by NBP-14 (Figure 5B; r2 = 0.45 P = 0.06). 
Furthermore, when the normal B-cells were excluded from 
the analysis the correlation was even stronger suggesting 
that tumor cells may be more reliant on T14 signaling 
in order to migrate (Figure 5C; r2 = 0.80 P = 0.006). 
Given that we had already established that there was 
variation in α7 nAChR expression between the cells under 
investigation, we set out to determine the effect of NBP-14 
on α7 nAChR expression. Figure 5D shows that MDA-
MB-231 cells showed a marked reduction in α7 nAChR 
expression following treatment with NBP-14. In contrast, 
MCF-7 cells showed only a small reduction in α7 nAChR 
expression under the same conditions. When considering 
all of the cell types together, there was a significant 
reduction in α7 nAChR expression following exposure to 
NBP-14 (Figure 5E; P = 0.04). Furthermore, there was a 
strong positive correlation between the NBP-14-mediated 
decrease in migration and the percentage decrease in 
α7 nAChR expression (Figure 5F; r2 = 0.83, P = 0.0016). 
Although we only analyzed α7 nAChR expression in a 
small cohort of primary CLL patients (n = 6), there was 
heterogeneity in basal α7 nAChR expression and also 
the degree of α7 nAChR inhibition induced by NBP-14 
(Supplementary Figure 3). 
DISCUSSION
Cancer recurrence at secondary locations, often 
years after effective treatment of the primary tumor, 
accounts for most of the mortality associated with solid 
tumors [13]. Furthermore, the ability of leukemia cells 
to infiltrate tissues and take advantage of pro-survival 
microenvironments likely contributes to their 
chemoresistance. Therefore, understanding the cellular 
processes that promote metastasis and clinical relapse is 
of critical importance. In this regard, the identification of 
novel therapeutic targets is of particular interest because 
they are less likely to be subject to the common drug 
resistance mechanisms encountered following treatment 
with chemotherapy or immunotherapy [14]. 
AChE has been implicated in tumorogenesis for 
almost 50 years [6], in many cases in a capacity not 
linked to its conventional enzymatic role in cholinergic 
transmission [7]. Of particular interest is the observation 
that in metastatic mode, there is a shift from a high 
level of tetramers, to a higher proportion of dimers 
and monomers [8]. One interpretation of this change in 
oligomerization pattern is that during metastasis there 
is an enhanced availability of free C-terminal peptide 
resulting in significantly increased levels of endogenous 
T14. A role for T14 in metastases was previously 
inferred by the effects of exogenous T14 on the highly 
metastatic breast cancer cell line MDA-MB-231 [10]. 
Recently a cyclized peptide, NBP-14, has been shown to 
antagonize the effects of T14 in brain tissue [15]. Using 
this new agent, we set out to assess whether α7 nAChR 
antagonism could provide a novel therapeutic target in 
human cancers. In particular, we wanted to establish 
whether this peptide could impact upon the migratory 
capacity of a range of tumor cell lines and primary CLL 
cells. We compared our findings with those obtained 
using normal B-cells. 
As a first step, we confirmed that all of the cells under 
evaluation in this study expressed the α7 nAChR. We noted 
variation in receptor expression but this was not associated 
with the modest cytotoxic or anti-proliferative effects 
induced by NBP-14. It was of considerable interest that we 
were able to detect the active T14 peptide in both cellular 
extracts and the media that they were cultured in. Indeed, 
we were able to demonstrate a strong positive correlation 
between the intracellular levels of T14 and the expression 
of the α7 nAChR (r2 = 0.91). Furthermore, there was an 
inverse correlation between T14 detected in the culture 
media and expression of the α7 nAChR (r2 = −0.79).
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Figure 3: (A) Cell migration in transwells was quantified over after 24 h and the mean baseline percentage migration for each of the cell 
lines and primary cells were arranged in descending order. (B) There was a positive correlation (r2 = 0.31) between percentage baseline 
migration and α7 nAChR expression. (C) The inhibitory effect on migration induced by NBP-14 was dose-dependent up to 1 mM for each 
of the six cancer cell lines tested. Comparison of the anti-migratory responses induced by 1mM of the T15, T30 and NBP-14 peptides in (D) 
primary CLL cells and (E) primary normal B-cells. (F) Although there was no statistical difference in baseline migration between normal 
B-cells and CLL B-cells, 1 mM NBP-14 preferentially inhibited the migration of primary CLL cells when compared with normal B-cells.
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Figure 4: The anti-migratory responses induced by the T15, T30 and NBP-14 peptides were assessed in transwell experiments conducted 
over 24 h in (A) MDA-MB-231 cells (B) MCF-7 cells (C) JJN3 cells (D) H929 cells (E) MEC-1 cells and (F) KG1a cells. All of the cell 
lines, apart from MCF7 cells, showed a significant reduction in migration following co-incubation with 1mM NBP-14. The T30 peptide 
had more variable effects on the cell lines but in every case the inert T15 peptide had no significant impact on the migration of the cells. All 
data are presented as mean (± SD) of five independent experiments.
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Figure 5: The change in migration induced by 24 h exposure to NBP-14 was calculated for each cell type. (A) shows the 
mean percentage decrease in migration induced by 1mM NBP-14 for each of the cell lines and primary cells arranged in descending order. 
(B) We next plotted the change in migration induced by NBP-14 against the percentage baseline migration. These parameters were positively 
correlated (r2 = 0.45) and (C) was strengthened when the normal B-cell data was excluded (r2 = 0.80). (D) In parallel experiments, we 
assessed the effect of exposure to 1 mM NBP-14 on the surface expression of the α7 nAChR on MCF7 and MDA-MB-231 cells. NBP-14 
caused a reduction in α7 nAChR expression on both cell lines; this was most apparent on MDA-MB-231 cells, which manifest higher 
constitutive expression of the receptor. (E) Analysis of the other cell lines and primary cells confirmed that α7 nAChR expression was 
significantly reduced following exposure to 1 μM NBP-14 for 72 h. (F) Furthermore, the decrease in migration induced by NBP-14 strongly 
correlated with the decrease in α7 nAChR expression (r2 = 0.83).
Oncotarget9www.impactjournals.com/oncotarget
Despite its lack of potency as a cytotoxic/cytostatic 
agent, NBP-14 was able to preferentially inhibit the 
migration of tumor cells when compared to normal B-cells. 
Moreover, the exogenous, linear peptide T30, when applied 
alone or in combination with NBP-14 had no significant 
effect on migration when compared with NBP-14 
alone in any of the cell lines and primary cells evaluated. 
This could be due to a ceiling effect of endogenous T14 
preventing any further effects of exogenous T30. This 
concept was supported by the observation that the most 
migratory cells manifested the highest levels of α7 nAChR, 
the lowest levels of extracellular T14 but the highest 
levels of intracellular T14. This implies that these cells are 
capable of scavenging T14 from their microenvironment 
resulting in optimal intracellular signaling. Exposure to the 
cyclized variant, NBP-14, caused a significant reduction 
in surface expression of α7 nAChR presenting a plausible 
mechanism for blocking the actions of endogenous T14. 
Primary CLL cells showed baseline heterogeneity 
in both their α7 nAChR expression and their migratory 
capacity. However, NBP-14 was able to significantly 
reduce migration in all of the primary tumor samples 
tested. It is of particular interest that although normal 
B-cells showed a similar level of baseline migration to 
leukemic B-cells, they were significantly less sensitive to 
the anti-migratory effects of NBP-14 (P = 0.0002). This 
implies normal B-cells are not as dependent on the effects 
of α7 nAChR signaling as their malignant counter-parts 
presenting the potential for a positive therapeutic index 
when inhibiting this target. A rationale for these observed 
differential effects is that normal B-cells expressed less 
α7 nAChR when compared with leukemic B-cells. This 
concept was further supported by the finding that there 
was a strong positive correlation between the reduction 
in α7 nAChR expression and the reduction in migration 
induced by NBP-14 in all of the cell lines and primary 
cells evaluated. 
In conclusion, the findings of this study support 
the concept that antagonizing α7 nAChR signaling 
in human cancers represents a promising therapeutic 
strategy. Although the precise downstream consequences 
of α7 nAChR signaling remain unresolved, it is clear 
that the molecular targets relate to migration rather than 
proliferation and survival. This raises the possibility of 
combining α7 nAChR antagonists, such as the novel agent 
NBP-14 described here, with other anti-cancer agents both 
in the frontline and relapsed/refractory settings.
MATERIALS AND METHODS
Culture conditions for cancer cell lines, primary 
CLL cells and normal B-cells
Primary chronic lymphocytic leukemia (CLL) 
cells were obtained from patients attending outpatients’ 
clinics at the University Hospital of Wales with informed 
consent in accordance with the ethical approval granted 
by South East Wales Research Ethics Committee 
(02/4806). Normal B-cells were obtained from healthy 
volunteers again with informed consent. All of the cell 
lines were purchased from DSMZ and were used for these 
experiments within 6 months of purchase. In each case 
multiplex PCR of minisatellite markers revealed a unique 
DNA profile and were shown to be mycoplasma-free. All 
of the cell lines, the primary CLL cells and normal B-cells 
were maintained in RPMI medium supplemented with 
100 units/ml penicillin, 100 µg/ml streptomycin and 10% 
fetal calf serum. In addition, 100 µM of acetylcholine 
(Sigma) was added to the culture media to ensure that 
the availability of acetylcholine was not a limiting factor 
in these experiments. Cells were treated with a range of 
concentrations of peptide (0–10 µM); all peptides (T15, 
T30 and NBP-14) were all synthesized by Genosphere 
Biotechnologies.
Purification of CLL and normal B-cells
Freshly isolated peripheral blood B-cells derived 
from CLL patients and healthy volunteers were isolated 
from whole blood by positive selection using CD19 
microbeads on an AutoMACS Pro separator (Miltenyi 
Biotec.). Cell purity was subsequently checked using an 
Accuri C6 flow cytometer (BD Biosciences) after staining 
an aliquot of cells with a fluorescein isothiocyanate-labeled 
CD20 antibody (Biolegend). In every case > 94% of the 
cells analyzed were expressing CD20.
Measurement of in vitro apoptosis
Aliquots of each cell type (1 × 106 cells) were 
cultured for 72 h, harvested by centrifugation (300 g for 
5 mins) and then resuspended in 195 µL of calcium-rich 
buffer. Subsequently, 5 µL of Annexin V (eBiosciences) 
was added to the cell suspension and cells were incubated 
in the dark for 10 mins prior to washing. Cells were finally 
resuspended in 190 µL of calcium-rich buffer together 
with 10 µL of propidium iodide. Apoptosis was assessed 
by dual-color immunofluorescent flow cytometry using an 
Accuri C6 flow cytometer and data were analyzed using 
CFlow software (BD Biosciences). 
Measurement of in vitro proliferation
Cultured cells were harvested by centrifugation 
and were then counted using a Vi-Cell XR cell viability 
counter (Beckman Coulter). The number of viable cells 
in each culture was then expressed as a percentage of the 
viable cells in the control cultures (no peptide). 
Western blotting 
Whole cell pellets (1 × 106 cells) from eight cancer 
cell lines (MEC-1, KG1a, JJN3, H929, MCF-7, MDA-
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MB-231, primary CLL cells and normal B-cells) were 
solubilized in 1 x Lysis Buffer (20 mM Tris Base, 137 mM 
NaCl, 1% Tween-20, 2 mM EDTA) containing protease 
inhibitor cocktails (Phosphatase 1:1, PMSF 1:1, aprotinin 
1:1) with a 17% v/v ratio. Subsequently, the mixture was 
triturated using a Polytron for 10 seconds and shaken at 
4oC for 2 h. Then, the samples were centrifuged at 13,000 g 
for 30 minutes at 4oC and the supernatants were taken and 
stored at −80oC. Protein concentrations were determined 
in the cell lysate samples above and their corresponding 
culture media samples using the Pierce™ 660 nm Protein 
Assay (Thermo Scientific, 22660). Subsequently, Western 
blot analysis was conducted on the samples using the 
previous established method [15]. The primary antibodies 
used were anti-T14 antibody (1:1000) [15], GAPDH 
(abcam, Ab181602, 1:1000) and anti- α7 nAChR (abcam, 
Ab10096, 1:1000). The secondary antibody used was goat 
anti-rabbit antibody conjugated to horseradish peroxidase 
(Abcam, ab6721, 1:5000). Protein bands derived from 
the cell lysates were quantified using Image J, measuring 
total optical intensity, and were subsequently normalized 
to the GAPDH loading control. In the case of the culture 
supernatants, T14 and α7 nAChR expression were 
normalized to total protein levels using Blot FastStain [16] 
to control for loading error. 
Flow cytometric analysis of Alpha-7 nicotinic 
receptor expression
Aliquots of 1 × 106 cells from each cell line or 
primary cell sample were harvested by centrifugation, 
resuspended in 100 µL staining buffer (PBS + 5% FCS) 
and then labeled with 10 µL anti-α7 nAChR antibody 
directly conjugated with phycoerythrin (Santa Cruz 
Biotech., Sc-58607-PE). Cells were incubated with 
primary antibodies at 4oC for 20 min in the dark to prevent 
photobleaching. The cell suspension was then washed 
in 1 mL of staining buffer and prior to resuspension in 
200 µL of 1% paraformaldehyde solution. At least 10,000 
cells were analyzed using an Accuri C6 flow cytometer 
(Becton Dickinson) and data were expressed as mean 
fluorescence intensity (MFI) values. In order to control 
for autofluorescence, the α7 nAChR MFI values were 
corrected by subtracting the FL2 MFI values derived from 
the analysis of unlabeled cells. 
Drugs and reagent 
Acetylthiocholine chloride was provided by Sigma-
Aldrich, A5626.  T30, T15 and NBP14 were synthesized 
by Genosphere Biotechnologies (France). 
Migration assays
In vitro migration assays were performed by using 
6.0 μm pore size transwell migration plates (Costar, 
Corning). Aliquots (1 × 106 cells) of each cell type in 
500 μl of supplemented RPMI media were mixed with the 
appropriate concentration of peptide and were then added 
to the upper chamber of the transwell insert. 100 ng/ml 
of CXCL12 was added to the baso-lateral chamber for all 
the cell types tested apart from KG1a cells. KG1a cells do 
not express CXCR4 and so are unresponsive to CXCL12. 
Instead, media containing 20% fetal calf serum was 
added to the baso-lateral chamber in these experiments. 
The plates were incubated for 24h at 37°C in 5% CO2 
in the presence of the peptides (T15, T30, NBP-14 and 
the combination of T30+NBP−14) at concentrations 
between 0.1 nM and 10 µM. In addition, control cultures 
were carried out to which no peptide was added. Cells 
were subsequently harvested by centrifugation and were 
analyzed by flow cytometry using an Accuri C6 flow 
cytometer (BD). None of the conditions tested induced 
significant cell death in the cultures. Migration of CLL 
cells was determined by counting cells that migrated to 
the lower (baso-lateral) chamber of the transwell plate and 
then expressed as a percentage of the total number of cells 
initially added to the upper (apical) chamber.
Statistical analysis
The data obtained in these experiments were 
evaluated using the Wilcoxon signed rank test and 
correlation coefficients were calculated from least squares 
linear regression plots. LD50 values were calculated from 
line of best-fit analysis of the dose-response curves. All 
statistical analyses were performed using Graphpad Prism 
6.0 software (Graphpad Software Inc., San Diego, CA). 
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